{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T15:36:41Z","timestamp":1782401801156,"version":"3.54.5"},"reference-count":27,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"unspecified","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,4,17]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To establish the prevalence of clinically significant chronic obstructive pulmonary disease (COPD) and relevant characteristics in individuals with a significant smoking history who are hospitalised for acute myocardial infarction (MI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Cross-sectional study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Hospital inpatients at 8 European centres (7 in Sweden, 1 in the UK).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>518 men or women (302 in Sweden, 216 in the UK) hospitalised for acute MI, aged 40 years or older, with a smoking history of at least 10 pack-years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>\n                      The primary outcome was prevalence of detected significant COPD (Global Initiative for Chronic Obstructive Lung Disease stages 2\u20134), defined as a ratio of forced expiratory volume in 1 and 6\u2009s (FEV\n                      <jats:sub>1<\/jats:sub>\n                      \/FEV\n                      <jats:sub>6<\/jats:sub>\n                      ) &lt;0.7\u2009and FEV\n                      <jats:sub>1<\/jats:sub>\n                      &lt;80% of the predicted value, measured using microspirometry. Secondary outcome measures were prior diagnosis of COPD, prescription of inhaled corticosteroids (ICS), symptom burden (COPD Assessment Test (CAT)) and blood eosinophil count.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The prevalence of significant COPD was 91\/518 (18% (95%\u2009CI 14 to 21)) with no difference between the countries. Of those with detected significant COPD, 69 (76%) had no previous COPD diagnosis. A CAT score &gt;10 was found in 65%, and a blood eosinophil count of \u2265100\/mm\n                      <jats:sup>3<\/jats:sup>\n                      and \u2265300\/mm\n                      <jats:sup>3<\/jats:sup>\n                      was found in 76% and 20%, respectively. Inhaled corticosteroids were used by 15% of the patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a cohort of patients hospitalised for acute MI in Sweden and the UK, one in five patients with a history of smoking was found to have significant COPD based on microspirometry. Symptom burden was high and treatment rates with ICS low. Among those diagnosed with COPD, three out of four had not been previously diagnosed with COPD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-097851","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T01:35:35Z","timestamp":1746754535000},"page":"e097851","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Prevalence of microspirometry-detected chronic obstructive pulmonary disease in two European cohorts of patients hospitalised for acute myocardial infarction: a cross-sectional study"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct06283966","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7822-8852","authenticated-orcid":false,"given":"William A E","family":"Parker","sequence":"first","affiliation":[{"name":"Cardiovascular Research Unit, The University of Sheffield, Sheffield, UK"},{"name":"NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefin","family":"Sundh","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Orebro Universitet, Orebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Oldgren","sequence":"additional","affiliation":[{"name":"Medical Sciences, Uppsala University, Uppsala, Sweden"},{"name":"Uppsala Clinical Research Center, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontus","family":"Andell","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden"},{"name":"ME Cardiology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Reitan","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Jernberg","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Hofmann","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, Division of Cardiology, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4242-9801","authenticated-orcid":false,"given":"Moman A","family":"Mohammad","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Clinical Sciences, Lunds Universitet, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Erlinge","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Clinical Sciences, Lunds Universitet, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Akerblom","sequence":"additional","affiliation":[{"name":"Medical Sciences, Uppsala University, Uppsala, Sweden"},{"name":"Uppsala Clinical Research Center, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia Sederstam","family":"Lawesson","sequence":"additional","affiliation":[{"name":"Department of Cardiology Department of Health, Medicine and Caring Sciences, Link\u00f6ping University, Linkoping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriakos V","family":"Konstantinidis","sequence":"additional","affiliation":[{"name":"Projects, Early Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Lindb\u00e4ck","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5093-6980","authenticated-orcid":false,"given":"Christer","family":"Janson","sequence":"additional","affiliation":[{"name":"Medical Sciences, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4288-3310","authenticated-orcid":false,"given":"Anna","family":"Bj\u00f6rkenheim","sequence":"additional","affiliation":[{"name":"Department of Cardiology, \u00d6rebro University Hospital, Orebro universitet, Orebro, Sweden"},{"name":"Faculty of Medicine and Health, School of Medical Sciences, Orebro universitet, Orebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadir","family":"Elamin","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Unit, Division of Clinical Medicine, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"McMellon","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Unit, Division of Clinical Medicine, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Moyle","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Unit, Division of Clinical Medicine, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul","family":"Patel","sequence":"additional","affiliation":[{"name":"Clinical Development, Late Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jad","family":"El-Khoury","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Respiratory, BioPharmaceutical Medical, AstraZeneca plc, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raulin","family":"Surujbally","sequence":"additional","affiliation":[{"name":"Clinical Operations - Late Respiratory and Immunology, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F","family":"Storey","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Unit, The University of Sheffield, Sheffield, UK"},{"name":"NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan K","family":"James","sequence":"additional","affiliation":[{"name":"Medical Sciences, Uppsala University, Uppsala, Sweden"},{"name":"Uppsala Clinical Research Center, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"2025120521021351000_15.5.e097851.1","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2466-11-36","article-title":"Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema","volume":"11","author":"Forey","year":"2011","journal-title":"BMC Pulm Med"},{"key":"2025120521021351000_15.5.e097851.2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7137.1043"},{"key":"2025120521021351000_15.5.e097851.3","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2013-000002","article-title":"Impact of chronic obstructive pulmonary disease on morbidity and mortality after myocardial infarction","volume":"1","author":"Andell","year":"2014","journal-title":"Open Heart"},{"key":"2025120521021351000_15.5.e097851.4","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1164\/rccm.201911-2207OC","article-title":"Reduction in All-Cause Mortality with Fluticasone Furoate\/Umeclidinium\/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease","volume":"201","author":"Lipson","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2025120521021351000_15.5.e097851.5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202006-2618OC"},{"key":"2025120521021351000_15.5.e097851.6","unstructured":"Global initiative for chronic obstructive lung disease . 2024 gold report. 2024. Available: https:\/\/goldcopd.org\/2024-gold-report\/"},{"key":"2025120521021351000_15.5.e097851.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"2025120521021351000_15.5.e097851.8","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201804-0621CI"},{"key":"2025120521021351000_15.5.e097851.9","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euad193","article-title":"Implementation of a screening and management pathway for chronic obstructive pulmonary disease in patients with atrial fibrillation","volume":"25","author":"van der Velden","year":"2023","journal-title":"Europace"},{"key":"2025120521021351000_15.5.e097851.10","doi-asserted-by":"crossref","DOI":"10.1038\/s41533-018-0083-9","article-title":"Point of care microspirometry to facilitate the COPD diagnostic process in primary care: a clustered randomised trial","volume":"28","author":"Schermer","year":"2018","journal-title":"NPJ Prim Care Respir Med"},{"key":"2025120521021351000_15.5.e097851.11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1513\/AnnalsATS.201308-251OC","article-title":"FEV(1)\/FEV(6) to diagnose airflow obstruction. Comparisons with computed tomography and morbidity indices","volume":"11","author":"Bhatt","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"2025120521021351000_15.5.e097851.12","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1093\/eurheartj\/ehy655","article-title":"What\u2019s new in the Fourth Universal Definition of Myocardial infarction?","volume":"39","author":"Thygesen","year":"2018","journal-title":"Eur Heart J"},{"key":"2025120521021351000_15.5.e097851.13","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2147\/COPD.S136244","article-title":"Multicenter study of the COPD-6 screening device: feasible for early detection of chronic obstructive pulmonary disease in primary care?","volume":"12","author":"Kjeldgaard","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025120521021351000_15.5.e097851.14","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00102509"},{"key":"2025120521021351000_15.5.e097851.15","doi-asserted-by":"crossref","DOI":"10.1038\/s41533-019-0158-2","article-title":"Accuracy of Vitalograph lung monitor as a screening test for COPD in primary care","volume":"30","author":"Dickens","year":"2020","journal-title":"NPJ Prim Care Respir Med"},{"key":"2025120521021351000_15.5.e097851.16","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.05.020415","article-title":"Global and regional estimates of COPD prevalence: Systematic review and meta-analysis","volume":"5","author":"Adeloye","year":"2015","journal-title":"J Glob Health"},{"key":"2025120521021351000_15.5.e097851.17","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1136\/bmj.p2140","article-title":"\u201cSilent scandal\u201d of missing lung diagnostics in England\u2019s most deprived areas-where respiratory disease is most prevalent","volume":"382","author":"Howard","year":"2023","journal-title":"BMJ"},{"key":"2025120521021351000_15.5.e097851.18","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0139-2019"},{"key":"2025120521021351000_15.5.e097851.19","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-2029"},{"key":"2025120521021351000_15.5.e097851.20","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201711-2239OC"},{"key":"2025120521021351000_15.5.e097851.21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/eurheartj\/ehad486","article-title":"Inflammation in acute myocardial infarction: the good, the bad and the ugly","volume":"45","author":"Matter","year":"2024","journal-title":"Eur Heart J"},{"key":"2025120521021351000_15.5.e097851.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713901"},{"key":"2025120521021351000_15.5.e097851.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916046"},{"key":"2025120521021351000_15.5.e097851.24","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01219-2018","article-title":"Inhaled corticosteroids in COPD: friend or foe?","volume":"52","author":"Agusti","year":"2018","journal-title":"Eur Respir J"},{"key":"2025120521021351000_15.5.e097851.25","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.chest.2016.05.020","article-title":"Determinants of Smoking Cessation in Patients With COPD Treated in the Outpatient Setting","volume":"150","author":"T\u00f8ttenborg","year":"2016","journal-title":"Chest"},{"key":"2025120521021351000_15.5.e097851.26","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-216390"},{"key":"2025120521021351000_15.5.e097851.27","doi-asserted-by":"publisher","DOI":"10.1097\/MAT.0000000000001230"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-097851","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T05:02:25Z","timestamp":1764997345000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-097851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,8]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/bmjopen-2024-097851"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-097851","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}